FOSUN PHARMA (02196.HK): Repurchases 217,000 H shares for approximately HKD 3.587 million
NewTimeSpace News: On 27 August 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) voluntarily announced that, to safeguard the value of the Company, it repurchased an aggregate of 217,000 H shares in the open market on 27 August 2026 pursuant to the general mandate granted to the Board by shareholders at the annual general meeting, the H-share class meeting and the A-share class meeting held on 16 June 2026.
According to the announcement, the average repurchase price on that day was HKD 16.53 per share, with a total amount of approximately HKD 3.587 million, and the highest and lowest repurchase prices were HKD 16.59 and HKD 16.45 per share respectively. The repurchased H shares will be held by the Company as treasury shares, and their use will be determined based on factors including the H-share repurchase mandate and market conditions, including but not limited to cancellation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
- Fosun Pharma (02196.HK): DM1001 Preparation Obtains Clinical Trial Approval
- Fosun Pharma (02196.HK): Controlled Subsidiary’s HLX3902 Injection Obtains Clinical Trial Approval
- FOSUN PHARMA (02196.HK): Taohong Siwu Decoction Granules Registration Application Accepted by NMPA
- Fosun Pharmaceutical (02196.HK): Injection FXR0906 Approved for Clinical Trials
